NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., which files under the legacy SPAC ticker BRPA, is a post-combination biopharmaceutical company formed through the merger of Big Rock Partners Acquisition Corp — a blank-check vehicle sponsored by Big Rock Partners — with NeuroRx, Inc. Big Rock Partners Acquisition Corp completed its initial public offering in 2019, targeting the healthcare sector. The combined company, operating in critical-care and neurological medicine, filed an 8-K with the Securities and Exchange Commission on September 12, 2025. As a de-SPAC operating company, NRX Pharmaceuticals continues to navigate post-merger public-company obligations. Subscribers to SpacDesk can access the full filing history, sponsor profiles, and deal lifecycle data for BRPA and thousands of similar transactions — sign up today at SpacDesk.